-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28

Benzinga·09/29/2026 12:19:04
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.